Placenta plays active part in transferring vitamin D to foetus during pregnancy

A study led by Southampton researchers has shed new light on the role of the placenta in managing the relationships between maternal vitamin D and foetal development

The results, published in the journal eLife, demonstrate a complex interplay between vitamin D and the placenta.

They could help inform future initiatives that use vitamin D to support the development of unborn babies and enable women’s bodies to adapt well to pregnancy.

Lifelong health benefits

As vitamin D is unable to be produced by an unborn baby (a foetus), it must be transferred across the placenta. This is important for both their health in the womb and in later life.

Maternal vitamin D concentrations are positively associated with foetal bone growth and birth weight. These associations continue to hold true after birth and as they grow up.

Active not passive

Previous work has suggested that maternal vitamin D transfers passively across the placenta, but the current study challenges this idea.

“Research in kidneys has questioned the role of passive diffusion in the uptake of vitamin D,” explains Dr Claire Simner, Research Assistant at the University of Southampton.

“It has instead shown that this uptake is driven primarily by endocytosis of vitamin D, where the vitamin is bound to the binding protein albumin and introduced into the organ tissue cells.”

Simner is a co-first author of the study, alongside Dr Brogan Ashley, who was also at the University of Southampton at the time the work was carried out.

“We proposed that a similar endocytic mechanism exists in the placenta, suggesting that this organ plays an active role in the delivery of vitamin D to the foetus.”

Using real placentas

To explore this idea further, the team designed a study to find out how maternal vitamin D is taken up, metabolised and mediates gene expression within the human placenta.

They used a perfusion model – involving the use of human placental samples collected from term pregnancies immediately after delivery – and placental fragment cultures to study the behaviour of the organ tissue.

These methods contrast with cell-model approaches of previous research into how vitamin D transfers across the placenta.

To determine the mechanisms of placental vitamin D uptake, the team incubated fresh term human placental fragments with vitamin D alongside albumin for eight hours. They then analysed the gene expression of the fragments using a technique called quantitative rtPCR.

Active uptake with albumin

Their analysis revealed a significant increase in the expression of the CYP24A1 gene – which is involved in controlling the amount of vitamin D in the body – in the fragments following incubation, compared to fragments that were incubated with vitamin D only. This suggests that albumin might enable vitamin D uptake.

Professor Nicholas Harvey, Professor of Rheumatology and Clinical Epidemiology and NIHR Southampton Biomedical Research Centre researcher, was a co-senior author of the study, alongside Dr Jane Cleal, Lecturer in Epigenetics at the University of Southampton.

First to show active transfer

Additionally, the team demonstrated that vitamin D exposure leads to rapid effects on the full set of messenger RNA molecules (the transcriptome) and of proteins (the proteome) expressed by the placenta.

Their results revealed that the underlying epigenetic landscape of the placenta – the interaction between the genes and the environment – helps to dictate this transcriptional response to vitamin D treatment.

“This is the first quantitative study demonstrating the active transfer and metabolism of vitamin D by the human placenta, with widespread effects on the placenta itself,” Dr Cleal concludes.

“As our data are generated from term placenta only, additional studies are needed to determine how our findings relate to earlier stages of gestation.

“Together, the insights from our work and future research will be helpful for identifying potential new options for targeted interventions to improve pregnancy outcomes.”